Depemokimab for hypereosinophilic syndrome with frequent flares
Treatments studied
Part of Blood & lymphatic clinical trials.
This trial studies depemokimab, a medicine meant to reduce flares in people with hypereosinophilic syndrome (HES). It also checks how safe the treatment is and how well it works over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You weigh at least 40 kg at the first screening visit.
- You already have a documented diagnosis of hypereosinophilic syndrome (HES).
- You’ve had 2 or more HES flare-ups in the past 12 months.
- You can sign informed consent (you agree to take part).
- If you are pregnant or breastfeeding, you cannot join; if you could get pregnant, you must use highly effective birth control.
- Your prior HES treatment with steroid medicine (like OCS) should not be ineffective or non-responsive.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if dupilumab, added to your current treatment, can help with remaining symptoms of hypereosinophilic syndrome (HES) like asthma, eczema, nasal polyps, or eosinophilic esophagitis. You may qualify if you're already on a biologic therapy that lowers eosinophils but still have bothersome symptoms.
This study follows people with long-term high eosinophils (a type of white blood cell) and related conditions to learn how the illness changes over time. It helps doctors understand patterns of organ involvement and outcomes, which may improve future care.
This study follows families with a genetic condition that causes high levels of white blood cells called eosinophils. Researchers want to understand how the disease develops and changes over time to help predict who may get worse and how to treat it better.
This study tests an early treatment called depemokimab for people with moderate to severe COPD who have a type of inflammation linked to high eosinophils. It aims to reduce flare-ups and improve breathing.
This trial tests if a new medicine, depemokimab, can help children aged 6 to 11 whose asthma is not well controlled with their current inhalers and who have a type of inflammation called eosinophilic asthma. It may reduce asthma attacks and improve symptoms.
This trial tests a medicine called benralizumab for children with specific eosinophil-driven diseases (EGPA or HES). It aims to see if the drug can help control these conditions.
Hear when a new Hypereosinophilic Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.